DDEL-04. Pharmacokinetic/Pharmacodynamic analysis of the DNA methyltransferase inhibitor 5-azacytidine shows adequate brain tissue penetration with intravenous administration in a DIPG mouse patient-derived xenograft model.

One of the biggest obstacles in developing effective therapies for CNS tumors is drug delivery due to the enigmatic challenge of penetrating the blood-brain barrier. 5-azacytidine is a DNA methyltransferase inhibitor which was the first epigenetic targeting chemotherapeutic approved by the FDA. Alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Groves, Andrew, Jones, Kristen, Cameron, Amy, Panditharatna, Eshini, Morrow, Murry, Mozarsky, Brett, McCully, Cynthia, Peer, Cody, De Nguyen, Quang-, Filbin, Mariella, Warren, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Drug Delivery/Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164756/
http://dx.doi.org/10.1093/neuonc/noac079.125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164756/
http://dx.doi.org/10.1093/neuonc/noac079.125

Ejemplares similares